Management of Chronic Obstructive Pulmonary Disease (COPD)

Diagnosis and Classification

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria confirm the presence of irreversible bronchial obstruction with a FEV1/FVC ratio of less than 0.70, which is diagnostic for COPD in patients with a FEV1/FVC ratio of 0.68 (68%) 1, 2, 3
Spirometry post-bronchodilator is necessary to classify the severity of the disease and determine the percentage of predicted FEV1, which guides prognostic stratification 1, 4
The GOLD spirometric classification distinguishes between mild (FEV1 ≥80% predicted), moderate (50-80%), severe (30-50%), and very severe (<30%) COPD 1, 5

The American Thoracic Society recommends that smoking cessation is the single most important intervention that influences COPD outcomes at all stages of the disease, reducing the accelerated decline in FEV1 and representing the only treatment besides oxygen therapy that modifies prognosis 6, 7
The European Respiratory Society suggests that abrupt cessation has a higher success rate than gradual reduction of cigarette consumption 6, 8, 7
Combination pharmacotherapy, such as varenicline or bupropion plus nicotine replacement therapy, along with intensive behavioral counseling, is recommended for smoking cessation 6, 8, 7

The European Respiratory Society recommends that bronchodilators are the cornerstone of symptomatic treatment for the reversible component of bronchial obstruction 6, 4
Initiating treatment with a long-acting bronchodilator, such as a beta2-agonist (LABA) or a long-acting anticholinergic (LAMA, such as tiotropium), is suggested 4, 7
Short-acting beta2-agonists have a relatively rapid action and are recommended for "as-needed" use to relieve symptoms 6

The Centers for Disease Control and Prevention (CDC) recommend annual influenza vaccination to reduce severe illness, death, and risk of ischemic heart disease and total exacerbations in patients with COPD 7
Pneumococcal vaccines (PCV13 and PPSV23) should be administered to patients with COPD, especially those aged 80 years and older 7

The American College of Cardiology recommends aggressive assessment of cardiovascular diseases, as COPD and cardiovascular disease share common pathobiological pathways 4, 7
Screening for lung cancer, a significant cause of mortality in this population, is necessary 4
Assessing the need for long-term oxygen therapy in patients with severe COPD and hypoxemia, as it is the only treatment besides smoking cessation that improves prognosis, is crucial 4, 7

The European Respiratory Society suggests that when sputum becomes purulent, empirical treatment with a 7-14 day course of antibiotics is necessary 8
Common organisms include Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and viruses 8
Inexpensive antibiotics, such as amoxicillin, tetracycline derivatives, and amoxicillin/clavulanic acid, are sufficient in most cases 8

The American Thoracic Society recommends scheduling a follow-up visit within 2-4 weeks to assess progress in smoking cessation and symptomatic response 7
Regular spirometry should be performed to monitor disease progression 7
Reassessing inhaler technique at each visit is necessary, as 76% of patients with COPD make significant errors in using predosed inhalers 6, 7